🔎 Trials Near Me

Acasă › Leucemie acută bifinotipică › Michigan

Studii clinice pentru Leucemie acută bifinotipică în Michigan

4 studii pentru Leucemie acută bifinotipică caută participanți în Michigan.

Orașe în Michigan

Text oficial al studiului (în engleză)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • C S Mott Children's Hospital, Ann Arbor
  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
  • Bronson Methodist Hospital, Kalamazoo
În curs de recrutareFaza 2
365 Days · Toate sexele · Actualizat 25 sept. 2026 · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • C S Mott Children's Hospital, Ann Arbor
  • Children's Hospital of Michigan, Detroit
  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
  • și încă 2
În curs de recrutareFaza 3
365 Days – 25 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • C S Mott Children's Hospital, Ann Arbor
  • Children's Hospital of Michigan, Detroit
  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
  • și încă 2
În curs de recrutareFaza 1/2
Până la vârsta de 22 · Toate sexele · Actualizat 25 aug. 2026 · NCT04726241

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • C.S. Mott Children's Hospital, Ann Arbor
În curs de recrutareFaza 1
Vârste de la 1 la 21 · Toate sexele · Actualizat 6 dec. 2024 · NCT05476770

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.